Cadmus Rich - 19 Jan 2023 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role
Chief Medical Officer, Head of R&D
Signature
/s/ Julie Feder, as Attorney-in-Fact
Issuer symbol
AURA
Transactions as of
19 Jan 2023
Net transactions value
$0
Form type
4
Filing time
23 Jan 2023, 17:34:52 UTC
Previous filing
02 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURA Common Stock Award $0 +34,125 +139% $0.000000 58,703 19 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURA Stock Option (Right to Buy) Award +52,500 52,500 19 Jan 2023 Common Stock 52,500 $10.18 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant.
F2 The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments.

Remarks:

Chief Medical Officer, Head of R&D